JAK2/STAT3,LILRB4 Knockdown

Jianxian Xiong1,2, Jiayuan Ling3, Jie Yan4

  • 1Department of Cardiovascular Surgery, First Affiliated Hospital of Gannan Medical University, No. 23, Qingnian Road, Zhanggong District, Ganzhou City, 341000, Jiangxi Province, China.

Scientific reports
|July 6, 2024
PubMed
概括

白细胞免疫球蛋白样受体B4 (LILRB4) 敲除通过抑制热和JAK2/STAT3通路,提高了生存率并减少了大动脉剖析 (AD). 这为AD提供了潜在的治疗点.